Researchers identify a treatment for a rare bone loss disorder that might also lead to help for aging brittle bones
A possible ‘first-line’ treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Hajdu-Cheney syndrome is a rare genetic disease that leads to severe osteoporosis and developmental defects, including the reabsorption of bones in the hands and feet. The disease is associated with mutations in a particular gene, called NOTCH2, which codes for proteins involved with bone maintenance. The NOTCH2 proteins usually help balance destruction and construction essential for bone maintenance and repair. Mutations associated with Hajdu-Cheney syndrome upset that balance, but the exact mechanisms causing bone resorption have not been well understood.
Now, through a series of detailed tests, molecular biologist Hiroyuki Inuzuka and his colleagues have worked out the specific molecular pathway that results in Hajdu-Cheney syndrome.
They found that this particular NOTCH2 mutation does not maintain normal NOTCH2 protein abundance, with the help of another protein, called FBW7. To discover this, the researchers knocked out the gene for Fbw7 in the bones of mice. Without the gene and resulting protein, the mice had severe osteoporosis, much like people with Hajdu-Cheney syndrome — indicating that FBW7 is the primary regulator of this system.
They further determined that in humans with Hajdu-Cheney syndrome, the FBW7 protein was unable to bind to NOTCH2 proteins because the binding spot is missing in osteoclasts. This mutation allows the osteoclasts to over-operate, breaking down too much bone tissue.
The researchers were able to reverse bone loss in the knock-out mice with the elevated NOTCH2 by giving them a medication that blocks osteoclast formation. They tried several different treatments, including a chemical compound called DAPT that was particularly effective. DAPT has been shown to help with osteoarthritis by inhibiting function of NOTCH proteins in other studies. Using DAPT as well as Zoledronic acid, a common medication for osteoporosis, “may become a first-line treatment for Hadju-Cheney syndrome,” the researchers conclude in their study.
“By clearly identifying the relationship between FBW7 and NOTCH2 proteins, we have identified potential therapeutic targets for patients with rare bone diseases as well as much more widespread age-related osteoporosis,” said Inuzuka.
Learn more: Reversing severe bone loss
The Latest on: Bone loss
Bone and Joints Ingredients Market : Recent Industry Trends, Analysis and Forecast 2019
on April 17, 2018 at 2:30 pm
Soy isoflavone is another key bone health ingredient maintaining bone mineral density (BMD) and preventing bone loss. The most important ingredients of joint ingredient market are glucosamine and chondroitin. Collagen, eggshell membrane and olive ... […]
Augmented Baseplate Preserves Bone During Reconstruction
on April 16, 2018 at 8:11 pm
For those with a lesser degree of bone loss or correction, an augmented baseplate can provide benefits such as reduced bone removal, preservation of cortical bone, and lateralization. An augmented baseplate also provides a simple, reproducible method to ... […]
Bone and Mineral Metabolism Disorders Treatment Market Value Projected to Expand by 2025
on April 11, 2018 at 10:59 pm
Drugs utilized to treat osteoporosis are categorized into antiresorptive drugs (to reduce bone loss) and anabolic agents (to build bone). Major chemical classes under antiresorptive drugs are bisphosphonates, estrogen, selective estrogen receptor ... […]
Steroid-Induced Bone Loss Better Treated With Denosumab?
on April 10, 2018 at 9:10 am
The RANKL inhibitor denosumab (Prolia, Amgen) is more efficacious than the bisphosphonate risedronate in boosting bone mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, a new international, randomized ... […]
Animal study reveals causes and consequences of how bone cells “age”
on April 9, 2018 at 11:26 pm
... genetic bone disorders or chronic diseases have bone growth and mineral accrual that are often compromised and lead to bone loss, osteoporosis, and a high rate of bone fracturing.” One such factor contributing to this loss of bone, osteoporosis ... […]
Decoded: What causes bone loss
on March 10, 2018 at 3:57 am
New York, March 10 (IANS) The lack of a protein key to the control of inflammation may be responsible for rapid and severe bone loss, finds a study that could lead to improved care for older adults at higher risk for osteoporosis and gum disease. […]
Decoded: What causes bone loss
on March 10, 2018 at 3:27 am
The lack of a protein key to the control of inflammation may be responsible for rapid and severe bone loss, finds a study that could lead to improved care for older adults at higher risk for osteoporosis and gum disease. Inflammation is a necessary ... […]
Space radiation can cause bone loss in astronauts: study
on December 18, 2017 at 3:18 pm
Space radiation may cause astronauts in outer space to lose additional bone, but not more muscle, a study has found. The findings raise intriguing questions about the relationship between bone and muscle, especially for humans on Earth dealing with age ... […]
Dairy foods, vitamin D supplements may prevent bone loss
on March 2, 2017 at 1:13 am
Older adults who take Vitamin D supplements along with specific dairy foods such as milk, yogurt and cheese may have higher bone mineral density in their spine as well as guard them against bone loss in the hip, researchers led by one of Indian-origin has ... […]
via Google News and Bing News